Annexon Inc (NAS:ANNX)
$ 5.41 -0.09 (-1.64%) Market Cap: 576.67 Mil Enterprise Value: 275.75 Mil PE Ratio: 0 PB Ratio: 1.72 GF Score: 41/100

Annexon Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 03:30PM GMT
Release Date Price: $5.3 (+10.65%)
Anupam Rama
JP Morgan - Analyst

All righty. Let's go ahead and get started. Welcome everybody, to the Wednesday morning of the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analyst here at JPMorgan. I'm joined by Malcolm [Cunha] and Priyanka Grover from the team. Our first presenting company of today is Annexon. And speaking on behalf of the company, we have CEO, Doug Love. Doug?

Doug Love
Annexon, Inc. - President & CEO

Thank you, Anupam and JPMorgan. And thank all of you for joining us this morning. We're super excited to be here to talk about the robust complement pipeline that we have, targeting C1q in the classical pathway. We'll be making forward-looking statements this morning, and invite you to look at our materials on file.

So turning to our mission and who Annexon is, Annexon, frankly, is seeking to thrive by changing the lives of patients. We are focused on giving patients with complement-mediated disease, their lives back, by stopping or preventing them from being robbed of their

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot